Skip to main content

Research Repository

Advanced Search

Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications

Agboola, Ayodeji O.J.; Ebili, Henry O.; Iyawe, Victoria O.; Banjo, Adekunbiola A.F.; Salami, Babatunde A.; Rakha, Emad A.; Nolan, Chrstopher C.; Ellis, Ian O.; Green, Andrew R.


Ayodeji O.J. Agboola

Henry O. Ebili

Victoria O. Iyawe

Adekunbiola A.F. Banjo

Babatunde A. Salami

Professor of Breast Cancer Pathology

Chrstopher C. Nolan


Ku 70/80 is a regulator of the Non-Homologous End Joining (NHEJ) roles in clinicopathological features, and has prognostic significance in breast cancer (BC) in Caucasian populations. However, its significance in the Nigerian BC population, which is characterized by a higher rate of the triple-negative and basal phenotype, p53 mutation rate and BRCA1 deficiency, still needs to be investigated. We hypothesize that Ku70/80 expression shows adverse expression in Nigerian BC and, furthermore, that it is likely to have a therapeutic implication for Black BC management.
This study investigated the biological, clinicopathological and prognostic significance of Ku 70/80 expression in a BC cohort from a Nigerian population. Ku 70/80 expression was determined in 188 well-characterized formalin-fixed, paraffin-embedded (FFPE) BC samples using tissue microarray and immunohistochemistry. Ku 70/80 expression was correlated with clinicopathological, molecular and prognostic characteristics of patients.
Ku 70/80 was expressed in 113 (60.1%) tumors, and was positively associated with metastatic disease, triple-negative and basal phenotype, BRCA1 down regulators (MTA-1 and ID4), p-cadherin, PI3KCA and p53 expression. It inversely correlated with BRCA1, BRCA2, BARD1 and p27. Ku 70/80 was predictive of breast cancer-specific survival in multivariate analysis, but not of disease-free interval.
This study demonstrated that Ku 70/80 expression is associated with triple negativity and down-regulation of the homologous recombination pathway of DNA repair. Therefore, the development of novel drugs to target KU70/80 may improve the patients’ outcome in the treatment of Black BC.


Agboola, A. O., Ebili, H. O., Iyawe, V. O., Banjo, A. A., Salami, B. A., Rakha, E. A., …Green, A. R. (2017). Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. Pathology - Research and Practice, 213(1), 27-33.

Journal Article Type Article
Acceptance Date Oct 17, 2016
Online Publication Date Oct 25, 2016
Publication Date Jan 30, 2017
Deposit Date Oct 15, 2018
Publicly Available Date Oct 16, 2018
Journal Pathology - Research and Practice
Print ISSN 0344-0338
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 213
Issue 1
Pages 27-33
Keywords Pathology and Forensic Medicine; Cell Biology
Public URL
Publisher URL